Govt seeks Covid drug’s stock info to curb overcharging

The health ministry has asked the three companies making generic versions of Covid-19 drug Remdesivir in India to regularly give details of production, stocks and sales in the wake of complaints of shortage-driven blackmarketing and overcharging. The MRP of Remdesivir marketed by Hetero Healthcare Limited is Rs 5,400 but consumers have reported it being sold at a price of anywhere between Rs 15,000 to 60,000, a complaint to the health ministry said.